title: New strategies for triple-negative breast cancer--deciphering the heterogeneity.
abstract: Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biology. Exploring novel approaches to treatment of these subtypes is critical because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy. To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the standard treatment. We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.
authors.affiliation: Authors' Affiliations: Departments of Medicine and Cancer Biology; and Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
authors.forename: Vandana G
authors.initials: VG
authors.lastname: Abramson
authors.forename: Brian D
authors.initials: BD
authors.lastname: Lehmann
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Pietenpol
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D018740:Genetic Heterogeneity; D006801:Humans; D058990:Molecular Targeted Therapy; D059467:Transcriptome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents